Dengue Vaccine News

Takeda announced that its dengue vaccine, QDENGA, may be available in the market by the first half of 2027, as local processes are being completed. A partnershi

Japan's Takeda Pharmaceutical plans to reshape its India strategy with the approval of its new dengue vaccine, Qdenga, which is expected to launch commercially

India's first dengue vaccine, Qdenga, has arrived with a crucial safety caveat: it could enhance dengue in children who have not had a prior infection. In such

QDENGA, India's first dengue vaccine, has received approval for use, marking a significant advancement in the country's dengue prevention efforts.

India's drug regulator has approved Takeda's Qdenga, making it the first dengue vaccine available in the country, with expected availability in the first half o

India's first dengue vaccine has received approval from the DCGI and is expected to be available in the market next year.

India has approved QDENGA, a tetravalent dengue vaccine, with local production by Biological E expected to improve supply. Experts emphasize that vaccination sh

Takeda Biopharmaceuticals India has received market authorization from DCGI for its dengue vaccine, QDENGA, which is now approved for individuals aged four to s

India has approved Takeda's QDENGA, the first dengue vaccine, for individuals aged 4–60, providing a new tool to combat the rising burden of the disease.

India has approved Takeda's two-dose QDENGA vaccine for dengue, which can be administered to individuals aged 4 to 60 years without prior screening and protects

India's first dengue vaccine, Qdenga by Takeda, has been approved by the DCGI for individuals aged 4 to 60.